Cone-beam CT in lung biopsy: a clinical practice review on lessons learned and future perspectives
- PMID: 37675336
- PMCID: PMC10477635
- DOI: 10.21037/atm-22-2845
Cone-beam CT in lung biopsy: a clinical practice review on lessons learned and future perspectives
Abstract
Pulmonary nodules with intermediate to high risk of malignancy should preferably be diagnosed with image guide minimally invasive diagnostics before treatment. Several technological innovations have been developed to endobronchially navigate to these lesions and obtain tissue for diagnosis. This review addresses these technological advancements in navigation bronchoscopy in three basic steps: navigation, position confirmation and acquisition, with a specific focus on cone-beam computed tomography (CBCT). For navigation purposes ultrathin bronchoscopy combined with virtual bronchoscopy navigation, electromagnetic navigation and robotic assisted bronchoscopy all achieve good results as a navigation guidance tool, but cannot confirm location or guide biopsy positioning. Diagnostic yield has seen improvement by combining these techniques with a secondary imaging tool like radial endobronchial ultrasound (rEBUS) and fluoroscopy. For confirmation of lesion access, rEBUS provides local detailed ultrasound-imaging and can be used to confirm lesion access in combination with fluoroscopy, measure nodule-contact area length and determine catheter position for sampling. CBCT is the only technology that can provide precise 3D positioning confirmation. When focusing on tissue acquisition, there is often more than 10% difference between reaching the target and getting a diagnosis. This discrepancy is multifactorial and caused by breathing movements, small samples sizes, instrument tip displacements by tool rigidity and tumour inhomogeneity. Yield can be improved by targeting fluorodeoxyglucose (FDG)-avid regions, immediate feedback of rapid onsite evaluation, choosing sampling tools with different passive stiffnesses, by increasing the number biopsies taken and (future) catheter modifications like (robotic assisted-) active steering. CBCT with augmented fluoroscopy (CBCT-AF) based navigation bronchoscopy combines navigation guidance with 3D-image confirmation of instrument-in-lesion positioning in one device. CBCT-AF allows for overlaying the lesion and navigation pathway and the possibility to outline trans-parenchymal pathways. It can help guide and verify sampling in 3D in near real-time. Disadvantages are the learning curve, the inherent use of radiation and limited availability/access to hybrid theatres. A mobile C-arm can provide 3D imaging, but lower image quality due to lower power and lower contrast-to-noise ratio is a limiting factor. In conclusion, a multi-modality approach in experienced hands seems the best option for achieving a diagnostic accuracy >85%. Either adequate case selection or detailed 3D imaging are essential to obtain high accuracy. For current and future transbronchial treatments, high-resolution (CBCT) 3D-imaging is essential.
Keywords: Pulmonary nodules; cone-beam computed tomography (CBCT); early stage; lung cancer; navigation bronchoscopy.
2023 Annals of Translational Medicine. All rights reserved.
Conflict of interest statement
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-22-2845/coif). The series “Lung Cancer Management—The Next Decade” was commissioned by the editorial office without any funding or sponsorship. RLJV reports that his institution has received unrestricted funding from Philips, AstraZeneca, Johnson & Johnson, Siemens, Pentax, Galvanize Therapeutics, and Bioncise. Besides, his institution has received funding for consultancy from Johnson & Johnson, compensation for lecturing at educational events from Medtronic. He and his institution have patents planned, issued and pending. His institution has obtained compensation for travel fees for attending meetings from Pentax. He’s an unpaid board member of the Dutch Society of Technical Physicians. SEPK reports that his institution has received unrestricted research funding from Philips, AstraZeneca, Johnson & Johnson, Pentax, and Siemens. Besides, his institution has received fees for consultancy from Johnson & Johnson. INW and DKMW report that the institution has received research funding from Philips, AstraZeneca, Johnson & Johnson, and Pentax. EHFMH reports that his institution has received unrestricted research funding from Philips, AstraZeneca, Johnson&Johnson, Pentax, Galvanize Therapeutics, and Bioncise. His institution has received fees for consultancy from Johnson & Johnson and Philips, speaker’s fees from Janssen-Cilag and Pentax, and travel support from Pentax. He and his institution have patents planned, issued and pending. He’s an unpaid board member of the WABIP and EABIP. The authors have no other conflicts of interest to declare.
Figures



References
-
- Callister ME, Baldwin DR, Akram AR, et al. British Thoracic Society guidelines for the investigation and management of pulmonary nodules. Thorax 2015;70 Suppl 2:ii1-ii54. Correction appears in Thorax 2015;70:1188. - PubMed
Publication types
LinkOut - more resources
Full Text Sources